Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4261 Comments
1145 Likes
1
Quinncy
Active Reader
2 hours ago
Access real-time US stock market data with expert analysis and strategic recommendations focused on building a balanced and profitable portfolio. We help you diversify across sectors and industries to minimize concentration risk while maximizing growth potential.
👍 208
Reply
2
Suhanee
Senior Contributor
5 hours ago
I read this like it owed me money.
👍 157
Reply
3
Viriginia
Regular Reader
1 day ago
This feels important, so I’m pretending I understand.
👍 192
Reply
4
Wandy
Community Member
1 day ago
Really wish I had seen this sooner.
👍 92
Reply
5
Rhunette
Legendary User
2 days ago
Absolutely crushing it!
👍 112
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.